HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Phenprocoumon (Liquamar)

Coumarin derivative that acts as a long acting oral anticoagulant.
Also Known As:
Liquamar; Falithrom; Hexal Brand of Phenprocoumon; Marcoumar; Marcumar; Phenprogramma; Roche Brand of Phenprocoumon; Wörwag Brand of Phenprocoumon; Phenprocoumalol; Phenprocoumarol; Phenylpropylhydroxycumarinum; 2H-1-Benzopyran-2-one, 4-hydroxy-3-(1-phenylpropyl)-
Networked: 270 relevant articles (7 outcomes, 24 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1. Finsterer, Josef: 5 articles (07/2015 - 10/2003)
2. de Boer, Anthonius: 5 articles (04/2014 - 01/2008)
3. Stöllberger, Claudia: 4 articles (01/2015 - 10/2003)
4. Schmidt-Lucke, Caroline: 4 articles (01/2007 - 12/2003)
5. Nixdorff, Uwe: 4 articles (01/2007 - 12/2003)
6. Stellbrink, Christoph: 4 articles (01/2007 - 12/2003)
7. Redekop, William K: 3 articles (04/2014 - 06/2013)
8. Verhoef, Talitha I: 3 articles (04/2014 - 06/2013)
9. Rosendaal, Frits R: 3 articles (12/2013 - 06/2002)
10. Behr, Sigrid: 3 articles (05/2012 - 07/2010)

Related Diseases

1. Atrial Fibrillation
2. Thrombosis (Thrombus)
3. Stroke (Strokes)
4. Body Weight (Weight, Body)
01/01/1984 - "The model presented here is based on a phenprocoumon (PPC) standard dose calculated per kg body weight by adapting it to experimentally obtained mean values of biological half-life (t1/2) and relative volume of distribution (Vrel) of PPC taken from the literature. "
04/01/1994 - "The pharmacokinetics of phenprocoumon was studied in 24 healthy volunteers between the ages of 23 and 28 years and a mean body weight of 72 kg by intraindividual comparison of the plasma level after i.v. and oral administration of 9 mg phenprocoumon (PPC) or by the evaluation of the total plasma clearance of PPC by simultaneous measurement of the urinary excretion and of the plasma concentration after the administration of 9 mg PPC. "
03/01/1976 - "The first one was the control group without any manipulation, the second received an one-stage X-irradiation with 2500 R SD directed to the tail tumor, the third was treated with an oral dose of Phenprocoumon which was added to the daily drinking quantity (0.1 mg/kg body weight), and the fourth group was given an one-stage X-irradiation together with the oral Phenprocoumon treatment. "
02/01/2009 - "Consecutive patients receiving enoxaparin at a dosage of 1 mg/kg body weight/12 hours for temporary interruption of phenprocoumon were prospectively enrolled to the study. "
05/01/2013 - "Data were analyzed simultaneously using NONMEM VII. The model confirmed CYP2C9 and VKORC1 variants as the major predictors of variability in phenprocoumon concentrations and effects, together with body weight, age, comedication with CYP3A modifiers (i.e. "
5. Fibrosis (Cirrhosis)

Related Drugs and Biologics

1. Acenocoumarol
2. Warfarin (Coumadin)
3. Enoxaparin (Lovenox)
4. Digoxin (Digitek)
5. Prednisone (Sone)
6. Antipyrine (Phenazone)
7. Phenprocoumon (Liquamar)
8. Vitamin K
9. Heparin (Liquaemin)
10. coumarin

Related Therapies and Procedures

1. Electric Countershock (Cardioversion)
2. Plasmapheresis
3. Oral Administration
4. Transjugular Intrahepatic Portasystemic Shunt
5. Stents